Abstract: An eddy current flaw detecting probe includes a plurality of excitation coils (3) which is configured to generate an eddy current in an inspection target and a plurality of detection coils (4) which are differentially connected to each other. The plurality of detection coils (4) includes a first detection coil (41) which is disposed on a second center line (4a) intersecting a first center line (3a) which connects a center of a first excitation coil (31) and a center of a second excitation coil (32) to each other and a second detection coil (42) which is disposed on a side opposite to the first detection coil (41) on the second center line (4a). The excitation coil (3) and the detection coil (4) are disposed to be inclined toward an inspection target surface as approaching each other.

Abstract: The invention provides novel acoustic wave resonator devices and microbalances. More particularly, the invention provides quartz crystal microbalances with ultra-high sensitivity and methods of fabrication thereof.

Abstract: Computationally efficient, highly accurate, and cost-effective approach for detection of damage in a structure is described. Methods include a combined analysis in both global and local regions of a structure to predict the received wave signals at a location due to scattering of Lamb waves at a damage site. Through comparison of an actual received wave signal with the predicted signals, identification of damage location and/or type can be provided. Methods can be particularly beneficial when considering damage assessment in a complex structure that includes plate-like structures that include an extension off of a base plate, e.g., a stiffened structure.

Abstract: A crack detecting system includes a tool movable along a conduit or structure and having at least one sensing device for sensing cracks in a wall of the conduit or structure. The sensing device includes a fluid emitter and the fluid emitter includes at least one orifice configured to emit fluid. In response to the orifice emitting fluid, the emitted fluid excites the conduit or structure and the sensing device senses a response from the excitation of the conduit or structure. A processor is operable to process the response sensed by the sensing device and responsive to the processing, the processor determines flaws present at the wall of the conduit or structure.

Abstract: A sensor 30 including a plurality of elements 31 is divided into a plurality of regions 1 and 2. A UT device 20 is connected to each region of the sensor 30 via a switch 40. At least one region of the sensor 30 used for UT is selected for each flaw detection point according to a positional relation of the flaw detection point to the sensor 30. The UT device is connected to the selected at least one region of the sensor 30 by the switch 40. For a flaw detection point for which one region is selected, UT is performed by using the selected one region. For a flaw detection point for which a plurality of regions are selected, a necessary number of times of ultrasonic testing are performed according to a number of the regions by using the selected plurality of regions, and the results are subjected to addition processing.

Abstract: The invention relates to a method for checking an assembly comprising first (W1) and second (W2) joined substrates, comprising the following steps: a) transmitting an ultrasonic excitation signal towards the assembly by means of an ultrasonic transducer (301) located on the front face (A1) side of the first substrate (W1); b) measuring, using the transducer (301), an ultrasonic feedback signal including at least one echo (EF) of the excitation signal on the rear face (B2) of the second substrate (W2); c) calculating, using a processing circuit (303), a spectral signal representative of the change in frequency of an overall reflection coefficient of the assembly, defined as the ratio between the feedback signal measured in step b) and the excitation signal; and d) deriving, from said spectral signal, information relating to the quality of the bond between the first (W1) and second (W2) substrates.

Abstract: A method for a multistep analysis of a measuring program of a portable gas measuring device includes performing a factory setting of the portable gas measuring device, connecting a container having a known gas standard and performing a reference measurement, wherein a multidimensional reference measurement is recorded, selecting a measuring program for target materials from a list on the device, performing a measurement on a sample in dependence on the selected measuring program, wherein a multidimensional measured variable is recorded, automatically performing an analysis to identify at least one of the one or more target materials in the sample and the respective concentrations thereof, wherein the analysis is based on the multidimensional measured variable from the measurement on the sample, the multidimensional reference measurement for the gas standard, the values for the plurality of target materials or measuring programs, and the factory setting for the portable gas measuring device.

Abstract: A flow-through vial includes: a columnar internal space for containing a liquid; a liquid introduction part provided in a lower portion of a side surface for guiding the liquid to the internal space in a direction oblique to a radial direction in a horizontal cross section of the internal space; a liquid discharge part provided in an upper portion of the side surface for guiding the liquid in the internal space to outside; and an upper surface sealing member for sealing an upper surface of the internal space, the upper surface sealing member being made of an elastic material which can be penetrated by a needle descending from above.

Abstract: The invention relates to a method, to a device, and to the use of a method for the gas-chromatic separation and determination of volatile substances in a carrier gas by means of a chromatographic separating capillary (1), wherein the separating capillary and/or an enveloping capillary (2) surrounding the separating capillary (1) is electrically conductive and is heated with current in the form of a resistance heater and is cooled by a forced convective flow by means of a fluid in the form of a gradient flow field in such a way that a continuous temperature gradient arises over the length of the separating capillary.

Abstract: The present invention is a data-processing device used for a chromatograph which continuously performs a series of analyses for components in each sample while sequentially introducing a plurality of samples into a column. The device includes: an input section configured to allow for input of information into a schedule table for a plurality of analyses, the schedule table describing an analysis condition including a combination of the values of a plurality of control parameters, the order of execution of the plurality of analyses, and information for identifying a sample to be subjected to each analysis; a chromatogram creating means configured to receive data sequentially collected during two or more analyses and create a joint chromatogram from the data if the two or more analyses have been continuously performed for the same sample according to the schedule table; and a display means configured to display the joint chromatogram.

Abstract: The invention relates to a sensor device (1) for detecting a gas (G), particularly a permanent gas such as H2, CO, CO2, CH4, comprising: an adsorption filter (30) comprising a body (2) consisting of a molecular sieve material, a sensing element (10) for detecting said gas (G), and a carrier (4) for carrying the sensing element (10), wherein the carrier (4) comprises an opening (50) via which said gas (G) to be detected can reach the sensing element (10), and wherein the adsorption filter (30) is connected, particularly glued, to the carrier (4) and closes said opening (50) so that said gas (G) to be detected can diffuse through said body (2) towards the sensing element (10).

Abstract: Provided is a gas detection apparatus including: a main body in which a gas sensor is mounted; an inlet part disposed under the main body to introduce a gas present in a detection space; and a plurality of inlet holes formed to pass through the inlet part, wherein, in each of the inlet holes, an area of an inlet facing the detection space is greater than that of an outlet facing the main body.

Abstract: The invention is directed to a system for remote groundwater monitoring. The system includes one or more sensor modules configured for distribution in one or more groundwater monitoring wells. Each sensor module is adapted to acquire multi-parameter sensor data from each groundwater monitoring well. The multi-parameter sensor data includes electrochemical property data and electrical property data of groundwater in each groundwater monitoring well. One or more hubs are coupled to the one or more sensor modules for retrieving the multi-parameter sensor data and wirelessly communicating with an online server to upload the multi-parameter sensor data to the online server.

Abstract: Systems, methods and apparatus are provided for soil testing. In some embodiments, a soil sample quality criterion is determined and associated with the soil sample. In some embodiments a soil characteristic measurement is additionally taken and associated with the soil sample. In some embodiments, the soil sample and its associated data are associated with a container in which the soil sample is placed.

Abstract: Systems and methods for subterranean formation testing. A method may include lowering a formation testing tool into a subterranean formation, wherein the formation testing tool may comprise a plurality of chambers, a pump and a probe channel; extracting a fluid from the subterranean formation into the probe channel; determining fluid properties at different depths; generating a fluid property-depth gradient; moving the fluid into the plurality of chambers; and determining a concentration of an inorganic portion of a downhole flashed gas.

Abstract: An example system includes a core comprised of a dielectric material; a planar resonator on the core; a conduit containing the core and the planar resonator, with the conduit including an electrically-conductive material; and a coupling that is electrically-conductive and that connects the planar resonator to the conduit to enable the conduit to function as an electrical ground for the planar resonator.

Abstract: Provided is method for evaluating a cellulose nanofiber (CNF) dispersion, the method including: (1) a step of preparing 1.0 mass% of a CNF aqueous dispersion; (2) a step of adding a coloring material into the CNF aqueous solution and stirring with a vortex mixer; (3) a step of sandwiching a film of the coloring material-containing CNF aqueous dispersion between two glass plates such that said film has a thickness of 0.15 mm; (4) a step of observing, with a microscope, the film of the coloring material-containing CNF aqueous dispersion sandwiched between the two glass plates; (5) a step of sorting observed aggregates by size (diameter along major axis) thereof; and (6) a step of calculating a CNF dispersion index from the number of sorted aggregates and evaluating the dispersibility of the CNF aqueous dispersion.

Abstract: Embodiments of the present disclosure are directed to methods, systems and devices, for analyzing the molecules. For example, in some embodiments, a system is provided which includes a first volume of conducting fluid, a second volume of conducting fluid, an orifice in communication with the first and second volumes of fluid, and means for applying an electric potential difference between the first and second volumes of fluid. In some such embodiments, a conjugate product is provided which comprises charged polymers each having attached thereto at least one first molecule for analysis, where the product carries a predetermined charge greater than the charge on the first molecule, and upon dissolving the product in the first volume of fluid, the product is directed into the orifice.

Abstract: Provided are a first tank; a second tank; a thin film having a nanopore, which communicates the first tank to the second tank, and disposed between the first and second tanks; a first electrode provided in the first tank; and a second electrode provided in the second tank. A wall surface of the nanopore has an ion adsorption preventing structure to prevent desorption/adsorption of an ion contained in a solution filling the first tank and/or the second tank, and a voltage is applied between the first and second electrodes to measure an ion current flowing through the nanopore.

Abstract: The disclosed apparatus, systems and methods relate to ATPA technology that provides a method for the real-time assessment of the polymerization of a sample, e.g., whole blood or blood plasma coagulation, by a non-contact acoustic tweezing device. The acoustic tweezing technology integrates photo-optical tests used in plasma coagulation assays with mechanical (viscoelastic) tests used in whole blood analysis. Its key disruptive features are the increased reliability and accuracy due to non-contact measurement, low sample volume requirement, relatively short procedure time (less than 10 minutes), and the ability to assess the level of Factor XIII function from measurements of the fibrin network formation time.

Abstract: An electrical cartridge (1) for measuring blood coagulation includes at least: a container (11) having an opening portion (111) and a sample holding portion (112); a lid (12) including a sealing portion (121) configured to seal with at least part of the sample holding portion (112) and a shaft portion (122) extending from the sealing portion (121), wherein the container (11) is configured to engage with the lid (12) when the sealing portion (121) seals with the at least part of the sample holding portion (112); an electrode (13) secured to the sample holding portion (112); and at least one spring (123) configured to generate a pressing force on at least a portion of the lid (12) when the container (11) and the lid (12) are engaged, the pressing force being generated in a direction in which the lid (12) extends.

Abstract: A system for predicting diseases may accumulate information about the volatile, semi-volatile, and non-volatile organic compounds in breath/saliva. Such information may be analyzed over time to identify early disease indications, using non-invasive data collection via breath and alert patients directly for follow-up with a health professional.

Abstract: The present disclosure relates to an Extra Cellular Matrix composition specific for cancer type and a tumor microenvironment platform for long term culturing of tumor tissue, wherein said culturing provides human ligands and tumor tissue micro-environment to mimic physiologically relevant signalling systems. The present disclosure further relates to the development of a Clinical Response Predictor and its application in the prognostic field (selection of treatment option for the patient) and translational biology field (development of anticancer drugs). The disclosure further relates to a method of predicting clinical response of a tumor patient to drug(s). The disclosure further relates to a method for screening tumor cells for the presence of specific markers for determining the viability of said cells for indication of tumor status.

Abstract: The present invention relates to a method and tools for extracting information on a compounds influence on a cellular phenotype. The method of the invention may be used as a very efficient procedure for testing the efficacy or resistance of single drugs or combinations of drugs on cells from individual patients. Thus, the methods may be useful for predicting efficacy of a drug on a given patient. The methods are also useful for testing of compounds for toxicity, identifying drug targets for known or novel compounds.

Abstract: A method for down-regulating CD2AP expression in a subject comprises administering a CD2AP down-regulation composition to the subject, wherein the CD2AP down regulation composition is workable by way of siRNA/shRNA, CRISPR/Cas9, Talen or ZFNs; thereby the CD2AP expression in liver tissues of the subject is down-regulated.

Abstract: The present invention relates to a method for sorting highly effective mesenchymal stem cells for treating an immune disorder, the method comprising a step of measuring the level of an immunosuppressive biomarker following IFN-? pretreatment simulation in mesenchymal stem cells; highly effective mesenchymal stem cells sorted by the method; and a method for treating an immune disorder by using the highly effective mesenchymal stem cells. The present invention can provide a useful method capable of obtaining functionally excellent mesenchymal stem cells having an immune reaction regulation capability and used for clinically treating various immune disorders including graft-versus-host disease and autoimmune disorders, and thus can be usefully used as a therapy for immune disorders.

Abstract: The invention relates to methods for quantitating cell (e.g., epithelial cell) apical-basal polarity in three-dimensional multi-cell structures. The invention further relates to methods of using quantitation assays to screen for agents that modulate polarity, assess the risk of developing cancer, and monitor the effectiveness of cancer prevention programs.

Abstract: A blood-based sample from a cancer patient is subject to mass spectrometry and the resulting mass spectral data is classified with the aid of a computer to see if the patient is a member of a class of patients having a poor prognosis. If so, the mass spectral data is further classified with the aid of the computer by a second classifier which identifies whether the patient is nevertheless likely to obtain durable benefit from immunotherapy drugs, e.g., immune checkpoint inhibitors, anti-CTLA4 drugs, and high dose interleukin-2.

Abstract: This disclosure relates to a device to determine or quantify the presence of an analyte molecule, virus or cell of interest in a sample. The present disclosure also relates to a method to determine or quantify the presence of an analyte molecule, virus or cell of interest in a sample, a method of preparing the device of the disclosure, the use of the device of the disclosure for determining or quantifying the presence of an analyte molecule, virus or cell of interest in a sample and a kit of parts comprising the device of the disclosure.

Abstract: The present invention relates to a novel real-time multiplexed, multi-color BRET assay and apparatus for studying protein-protein interactions and determining various biological activities in live cells, wherein said assay is capable of capturing multiple signals simultaneously from a single sample and simultaneously over one or several wells. The real-time multiplexed, multi-color BRET assay is particularly useful for drug-screening, protein interactions, change of conformation of any channel or receptor subunits within live cells in response to potential drug candidates, thereby indicating activation or inhibition of said channel or receptor.

Abstract: The invention relates to unmasking endotoxins in compositions so that previously present, but undetectable endotoxins are rendered detectable.

Abstract: Embodiments of the present disclosure provide for polymer conjugates, methods of making the polymer conjugates, methods of using polymer conjugates, and the like, where the polymer conjugates include magnetic particles (e.g. iron oxide particles). Embodiments of the present disclosure can be advantageous for one or more of the following reasons: strong and rapid magnetic response, multiple types of agents can be attached to the polymer conjugate, the size of the polymer conjugate can be controlled, and the polymer conjugates can be produced in a cost-effective manner.

Abstract: This disclosure relates to a virus-like particle in which a small molecule-protein complex is entrapped, ensuring the formation of the small molecule-protein complex under physiological conditions, while protecting the small molecule-protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of small molecule-protein complexes.

Abstract: An object of the present invention is to provide a chromatographic medium having sufficiently improved storage stability. The present invention relates to a chromatographic medium having a detection part in which a detection substance composed of a protein is fixed, wherein the detection part includes a tri- or higher polysaccharide and a basic amino acid.

Abstract: A method of detecting a DSG2 autoantibody in a mammal is provided. The method includes contacting a biological sample obtained from a mammal with DSG2; and detecting the presence of DSG2 autoantibody bound to the DSG2 with a detectable anti-human antibody by detecting binding of the anti-human antibody to the DSG2 autoantibody. The method is useful to diagnose ARVC in a mammal.

Abstract: This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the analysis of cell-free nucleosomes in samples from individuals. Methods of the invention may include contacting cell-free nucleosomes from a biological fluid sample obtained from the individual with an antibody that binds specifically with a modified histone protein. Binding of the antibody to the nucleosomes is indicative that the individual has the disease condition.

Abstract: The invention includes a bioelectronic interface comprising a self-assembling unit, wherein the self-assembling unit comprises a variant GPCR fusion protein bound to an S-layer fusion protein. The invention also encompasses a biosensor or device comprising the bioelectronic interface and methods of screening for a ligand of a GPCR.

Abstract: A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

Abstract: The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.

Abstract: Provided are compositions and methods for determining whether or not an individual who has cancer is likely to develop immune-related adverse events (irAEs) because of treatment with an immune checkpoint inhibitor such as an anti-Programmed cell death protein 1 (anti-PD-1) checkpoint inhibitor, and/or anti-Cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) checkpoint inhibitor. Also provided are methods for treating an individual who has cancer with a checkpoint inhibitor and an agent to reduce the risk of toxicity from the checkpoint inhibitor, as well as administering agents to prevent or reduce the risk of toxicity during treatment.

Abstract: The present invention provides methods for treating cancer patients comprising assaying tumor tissue from patients and identifying those patients most likely to respond to treatment with a platinum-based agent, such as cisplatin, in combination with pemetrexed. Methods are provided for identifying those lung cancer patients most likely to respond to treatment with the combination of cisplatin+pemetrexed chemotherapy agents (“CDDP+PEM”) by determining expression patterns of a set of 38 specific proteins directly in tumor cells derived from patient tumor tissue using SRM mass spectrometry. The method further comprising determining if the patient will respond to treatment with combination therapy, and when proteomic analysis of patient tissue indicates that the patient will respond to treatment with combination therapy, the patient is administered a regimen that includes the pemetrexed/platinum agent combination.

Abstract: An object is to provide a test method for pancreatic cancer, and further to provide a test method for pancreatic cancer capable of detecting pancreatic cancer even at earlier stages. The objects are solved by a method for examining the likelihood of having pancreatic cancer, the method including (1) measuring the amount of at least one anti-carbohydrate antibody selected from the group consisting of anti-3-sialyllactose carbohydrate antibody and anti-(LN)3 carbohydrate antibody in a biological sample obtained from a subject, wherein the anti-3-sialyllactose carbohydrate antibody is an antibody capable of binding to a carbohydrate represented by Neu5Ac? (2?3) Gal? (1?4) Glc or an antibody recognizing the carbohydrate, and wherein the anti-(LN)3 carbohydrate antibody is an antibody capable of binding to a carbohydrate represented by Gal?1?3GlcNAc?1?3Gal?1?4GlcNAc or an antibody recognizing the carbohydrate.

Abstract: Methods are provided for quantifying the TYMS, TYMP, UCK1, UCK2, UPP1, OPRT, dCK, TK1, DPYD, CDA, RRM1, and/or RRM2 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM). The biological samples are chemically preserved with formaldehyde-containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein digest sample is prepared from the biological sample and the TYMS, TYMP, UCK1, UCK2, UPP1, OPRT, dCK, TK1, DPYD, CDA, RRM1, and/or RRM2 proteins are quantitated in the digest by SRM/MRM mass spectrometry.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.

Abstract: Provided herein are methods for identifying a compound that alters fluorescence resonance energy transfer (FRET) of a protein. In one embodiment, the method includes providing a target protein, where the target protein includes two heterologous domains, each domain having chromophores that together act as a FRET pair. In another embodiment, the method includes providing a target protein and a second protein, wherein the target protein includes a first heterologous domain including a chromophore, and the second protein includes a second heterologous domain including a chromophore, where the chromophores together act as a FRET pair. The method further includes contacting a sample including the target protein and optional second protein with a test compound to form a mixture, and measuring a fluorescence emission spectrum of the mixture during exposure to a light source.

Abstract: Related to is the technical field of light initiated chemiluminescence technology, and in particular, to a method for determining HD-Hook-effect sample, a system, a reagent kit, and a device for determining HD-Hook effect in immunoassay, an immunoassay method, a system, a reagent kit, and a device for determining immunoassay.

Abstract: The present invention relates to a method for diagnosing a skin displaying signs of dryness, based on the measurement of the level of expression of the gene encoding LCN1. The present invention also relates to a method for the cosmetic treatment of skin. The present invention also relates to a method for identifying a compound suitable for reducing and/or slowing the progression of the signs of dryness of a skin, as well as a kit.

Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Angiopoietin-related protein 6, Complement C5, Fibroblast growth factor 21, Fibroblast growth factor 23, Pro-interleukin-16, C—X—C motif chemokine 9, Hepatocyte growth factor-like protein, and/or Tumor necrosis factor receptor superfamily member 1 IB as diagnostic and prognostic biomarker assays in renal injuries.